These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23734246)

  • 21. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
    Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
    Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
    Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
    J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
    Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
    Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging.
    Kadayakkara DK; Korrer MJ; Bulte JW; Levitsky HI
    Cancer Res; 2015 Jan; 75(1):51-61. PubMed ID: 25388285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microdosed Lipid-Coated (67)Ga-Magnetite Enhances Antigen-Specific Immunity by Image Tracked Delivery of Antigen and CpG to Lymph Nodes.
    Ruiz-de-Angulo A; Zabaleta A; Gómez-Vallejo V; Llop J; Mareque-Rivas JC
    ACS Nano; 2016 Jan; 10(1):1602-18. PubMed ID: 26678549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of antitumor response by IL-2-transduced JAWS II dendritic cells.
    Rossowska J; Pajtasz-Piasecka E; Ryśnik O; Wojas J; Krawczenko A; Szyda A; Duś D
    Immunobiology; 2011 Oct; 216(10):1074-84. PubMed ID: 21676487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.
    Mitchell DA; Batich KA; Gunn MD; Huang MN; Sanchez-Perez L; Nair SK; Congdon KL; Reap EA; Archer GE; Desjardins A; Friedman AH; Friedman HS; Herndon JE; Coan A; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Sampson JH
    Nature; 2015 Mar; 519(7543):366-9. PubMed ID: 25762141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
    Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
    Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
    Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
    Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors.
    Walsh MP; Duncan B; Larabee S; Krauss A; Davis JP; Cui Y; Kim SY; Guimond M; Bachovchin W; Fry TJ
    PLoS One; 2013; 8(3):e58860. PubMed ID: 23554941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New perspectives in dendritic cell-based cancer immunotherapy.
    Nencioni A; Brossart P
    BioDrugs; 2001; 15(10):667-79. PubMed ID: 11604048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination.
    Gálvez-Cancino F; Roco J; Rojas-Colonelli N; Flores C; Murgas P; Cruz-Gómez S; Oyarce C; Varas-Godoy M; Sauma D; Lladser A
    Vaccine; 2017 Jul; 35(33):4148-4154. PubMed ID: 28666759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.
    Eggert AA; Schreurs MW; Boerman OC; Oyen WJ; de Boer AJ; Punt CJ; Figdor CG; Adema GJ
    Cancer Res; 1999 Jul; 59(14):3340-5. PubMed ID: 10416590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineering Strategies for Lymph Node Targeted Immune Activation.
    Chen Y; De Koker S; De Geest BG
    Acc Chem Res; 2020 Oct; 53(10):2055-2067. PubMed ID: 32910636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8
    Sanz-Ortega L; Portilla Y; Pérez-Yagüe S; Barber DF
    J Nanobiotechnology; 2019 Aug; 17(1):87. PubMed ID: 31387604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
    Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
    J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies.
    Winter H; Hu HM; Poehlein CH; Huntzicker E; Osterholzer JJ; Bashy J; Lashley D; Lowe B; Yamada J; Alvord G; Urba WJ; Fox BA
    Immunology; 2003 Mar; 108(3):409-19. PubMed ID: 12603608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.